| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jennifer Michaelson | Chief Scientific Officer | 2025-11-24 | 4,000 | $12.30 | $49.20kSell |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-28 | 165,667 | $8.40 | $1.39MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-17 | 32,217 | $7.84 | $252.58kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-16 | 150,000 | $8.86 | $1.33MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-15 | 51,500 | $7.94 | $409.06kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-14 | 15,032 | $7.59 | $114.05kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-10 | 277,298 | $7.36 | $2.04MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-09 | 626,043 | $6.70 | $4.19MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-08 | 556,300 | $6.46 | $3.59MBuy |
| Jacquelyn L. Sumer | Chief Legal Officer | 2025-02-25 | 3,756 | $8.53 | $32.04kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ansbert Gadicke | 27.35% | 16,157,644 | $199.71M | Insider |
| Lynx1 Capital Management LP | 15.17% | 8,963,500 | $110.79M | Insider |
| Ubs Oncology Impact Fund LP | 12.95% | 7,648,268 | $94.53M | Insider |
| Mpm Bioimpact LLC | 12.95% | 7,648,268 | $94.53M | Institution |
| Lynx1 Capital Management LP | 9.76% | 5,766,090 | $71.27M | Institution |
| Bvf Inc | 9.73% | 5,750,683 | $71.08M | Institution |
| Morana Jovanembiricos | 7.84% | 4,631,022 | $57.24M | Insider |
| Vision Scs F2 | 7.58% | 4,476,350 | $55.33M | Insider |
| F2 Bioscience I 2017 Ltd | 7.50% | 4,430,964 | $54.77M | Insider |
| Blackrock Inc | 7.06% | 4,169,962 | $51.54M | Institution |